West Pharmaceutical
755 hedge funds and large institutions have $17.8B invested in West Pharmaceutical in 2026 Q1 according to their latest regulatory filings, with 89 funds opening new positions, 265 increasing their positions, 281 reducing their positions, and 128 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
2.05% more ownership
Funds ownership: 96.59% → 98.64% (+2%)
6% less repeat investments, than reductions
Existing positions increased: 265 | Existing positions reduced: 281
6% less funds holding
Funds holding: 804 → 755 (-49)
7% less capital invested
Capital invested by funds: $19.1B → $17.8B (-$1.3B)
30% less first-time investments, than exits
New positions opened: 89 | Existing positions closed: 128
52% less call options, than puts
Call options by funds: $60.5M | Put options by funds: $126M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$290M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$284M |
| 3 |
JP Morgan Chase
New York
|
+$191M |
| 4 |
GIM
Generation Investment Management
London,
United Kingdom
|
+$170M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$150M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$218M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
-$150M |
| 3 |
SCM
Steadfast Capital Management
New York
|
-$118M |
| 4 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$67M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$62.4M |
WST Hedge Fund Activity: Q1 2026 in Review
755 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q1 2026, worth a combined $17.8B — down 6.8% from $19.1B a quarter earlier.
Sellers outnumbered buyers: 128 funds closed out of WST and 89 opened new positions — a net loss of 39 holders — while 281 trimmed existing stakes and 265 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $290M. The largest seller was Franklin Resources, cutting an estimated $218M.
- 755 institutional investors held West Pharmaceutical (WST) as of Q1 2026, down from 804 in Q4 2025.
- Funds reported $17.8B of West Pharmaceutical stock for Q1 2026, down 6.8% quarter-over-quarter.
- 89 funds opened new West Pharmaceutical positions in Q1 2026 and 128 closed out, a net change of -39 holders.
- The largest West Pharmaceutical buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $290M added.
- The largest West Pharmaceutical seller in Q1 2026 was Franklin Resources, an estimated $218M sold.
Based on aggregated 13F filings for Q1 2026.